<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090584</url>
  </required_header>
  <id_info>
    <org_study_id>BE-DRI (completed)</org_study_id>
    <nct_id>NCT00090584</nct_id>
  </id_info>
  <brief_title>Behavior Enhances Drug Reduction of Incontinence (BE-DRI)</brief_title>
  <acronym>BE-DRI</acronym>
  <official_title>Behavior Enhances Drug Reduction of Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to test if the addition of behavioral treatment to drug
      therapy for the treatment of urge incontinence will increase the number of patients who can
      discontinue drug therapy and sustain a significant reduction of incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Women Who Meet Definition of Success</measure>
    <time_frame>8 months</time_frame>
    <description>Proportion of women who meet definition of success: not taking drug or receiving other urge UI therapy (i.e., neuromodulation, botox injections, myomectomy, electrical stimulation, or any intravesical therapy) and not taking a tricyclic antidepressant or duloxetine at 8 months; and a &gt;70% reduction in number of incontinence episodes as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Incontinence Episodes</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Change from baseline to 10 weeks in number of incontinence episodes per week as reported on bladder diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Voids Per Day</measure>
    <time_frame>baseline and 10 weeks</time_frame>
    <description>Change from baseline to 10 weeks in frequency of voids per day as reported on bladder diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Distress</measure>
    <time_frame>baseline, 10 weeks and 8 months</time_frame>
    <description>Urogenital distress inventory (UDI). Higher score indicates greater distress. Possible range 0 to 300.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Bother</measure>
    <time_frame>baseline, 10 weeks and 8 months</time_frame>
    <description>Disease specific overactive bladder scale (OAB-q). HIgher score indicates greater bother. Possible range 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>10 weeks</time_frame>
    <description>Number of women who responded &quot;completely satisfied&quot; to question, &quot;How satisfied are you with your progress?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>8 months</time_frame>
    <description>Number of women who responded &quot;completely satisfied&quot; to question &quot;How satisfied are you with your progress?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Improvement</measure>
    <time_frame>10 weeks</time_frame>
    <description>Number of women who responded &quot;much better&quot; or &quot;better&quot; to question: &quot;Overall, do you feel that you are much better, better, about the same, worse or much worse?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Improvement</measure>
    <time_frame>8 months</time_frame>
    <description>Number of women who responded &quot;much better&quot; or &quot;better&quot; to question: &quot;Overall, do you feel that you are much better, better, about the same, worse or much worse?&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Urinary Incontinence (UI)</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug therapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>Drug therapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral training</intervention_name>
    <description>Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Female

          -  Urge predominant incontinence

          -  Incontinent &gt; 3 mos

          -  Available for 8 mos of followup

        Exclusion:

          -  Pregnancy or &lt; 6 mos post-partum

          -  Hypersensitivity to drug (tolterodine)

          -  Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple
             Sclerosis, spinal cord injury)

          -  History of extensive behavior treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William D Steers, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital and Medical Center</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uitn.net</url>
    <description>www.uitn.net</description>
  </link>
  <reference>
    <citation>Urinary Incontinence Treatment Network (UITN). Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study. Contemp Clin Trials. 2007 Jan;28(1):48-58. Epub 2006 Jun 18.</citation>
    <PMID>16919506</PMID>
  </reference>
  <reference>
    <citation>Borello-France D, Burgio KL, Goode PS, Markland AD, Kenton K, Balasubramanyam A, Stoddard AM; Urinary Incontinence Treatment Network. Adherence to behavioral interventions for urge incontinence when combined with drug therapy: adherence rates, barriers, and predictors. Phys Ther. 2010 Oct;90(10):1493-505. doi: 10.2522/ptj.20080387. Epub 2010 Jul 29.</citation>
    <PMID>20671098</PMID>
  </reference>
  <reference>
    <citation>Brubaker L, Lukacz ES, Burgio K, Zimmern P, Norton P, Leng W, Johnson H, Kraus S, Stoddard A. Mixed incontinence: comparing definitions in non-surgical patients. Neurourol Urodyn. 2011 Jan;30(1):47-51. doi: 10.1002/nau.20922.</citation>
    <PMID>21181960</PMID>
  </reference>
  <reference>
    <citation>Burgio KL, Kraus SR, Borello-France D, Chai TC, Kenton K, Goode PS, Xu Y, Kusek JW; Urinary Incontinence Treatment Network. The effects of drug and behavior therapy on urgency and voiding frequency. Int Urogynecol J. 2010 Jun;21(6):711-9. doi: 10.1007/s00192-010-1100-x. Epub 2010 Feb 9.</citation>
    <PMID>20143047</PMID>
  </reference>
  <reference>
    <citation>Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, Mallett V, Norton P, FitzGerald MP, Dandreo KJ, Richter HE, Rozanski T, Albo M, Zyczynski HM, Lemack GE, Chai TC, Khandwala S, Baker J, Brubaker L, Stoddard AM, Goode PS, Nielsen-Omeis B, Nager CW, Kenton K, Tennstedt SL, Kusek JW, Chang TD, Nyberg LM, Steers W; Urinary Incontinence Treatment Network. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med. 2008 Aug 5;149(3):161-9.</citation>
    <PMID>18678843</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald MP, Lemack G, Wheeler T, Litman HJ; Urinary Incontinence Treatment Network. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Nov;19(11):1545-50. doi: 10.1007/s00192-008-0687-7. Epub 2008 Aug 14.</citation>
    <PMID>18704249</PMID>
  </reference>
  <reference>
    <citation>Goode PS, Burgio KL, Kraus SR, Kenton K, Litman HJ, Richter HE; Urinary Incontinence Treatment Network. Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women. Int Urogynecol J. 2011 Mar;22(3):327-34. doi: 10.1007/s00192-010-1287-x. Epub 2010 Oct 13.</citation>
    <PMID>20945064</PMID>
  </reference>
  <reference>
    <citation>Markland AD, Richter HE, Kenton KS, Wai C, Nager CW, Kraus SR, Xu Y, Tennstedt SL; Urinary Incontinence Treatment Network. Associated factors and the impact of fecal incontinence in women with urge urinary incontinence: from the Urinary Incontinence Treatment Network's Behavior Enhances Drug Reduction of Incontinence study. Am J Obstet Gynecol. 2009 Apr;200(4):424.e1-8. doi: 10.1016/j.ajog.2008.11.023. Epub 2009 Feb 6.</citation>
    <PMID>19200939</PMID>
  </reference>
  <reference>
    <citation>Richter HE, Burgio KL, Chai TC, Kraus SR, Xu Y, Nyberg L, Brubaker L. Predictors of outcomes in the treatment of urge urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct. 2009 May;20(5):489-97. doi: 10.1007/s00192-009-0805-1. Epub 2009 Jan 30.</citation>
    <PMID>19183825</PMID>
  </reference>
  <reference>
    <citation>Zimmern P, Litman HJ, Mueller E, Norton P, Goode P; Urinary Incontinence Treatment Network. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. BJU Int. 2010 Jun;105(12):1680-5. doi: 10.1111/j.1464-410X.2009.09055.x. Epub 2009 Nov 13.</citation>
    <PMID>19912207</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald MP, Dubeau CE, Kraus SR, Johnson HW Jr, Rahn DD, Mallett V, Stoddard AM, Zyczynski HM; Urinary Incontinence Treatment Network. Patient expectations did not predict outcome of drug and behavioral treatment of urgency urinary incontinence. Female Pelvic Med Reconstr Surg. 2011 Sep;17(5):231-7.</citation>
    <PMID>22453106</PMID>
  </reference>
  <reference>
    <citation>Dyer KY, Xu Y, Brubaker L, Nygaard I, Markland A, Rahn D, Chai TC, Stoddard A, Lukacz E; Urinary Incontinence Treatment Network (UITN). Minimum important difference for validated instruments in women with urge incontinence. Neurourol Urodyn. 2011 Sep;30(7):1319-24. doi: 10.1002/nau.21028. Epub 2011 May 11.</citation>
    <PMID>21563210</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2004</study_first_submitted>
  <study_first_submitted_qc>August 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2004</study_first_posted>
  <results_first_submitted>August 27, 2012</results_first_submitted>
  <results_first_submitted_qc>May 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2013</results_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urge urinary incontinence (UUI)</keyword>
  <keyword>Drug/Behavior treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between July, 2004 and January, 2006 4,043 women were screened for eligibility and 561 provided written consent. After further screening, 134 were found to be ineligible, 119 withdrew consent and 1 was excluded erroneously. The remaining 307 were randomized to one of the treatment arms.</recruitment_details>
      <pre_assignment_details>Of the 134 found to be ineligible after consent, for 77 their urinary incontinence (UI) was not urge predominant, 19 had fewer than 7 episodes of incontinence per week and the other 38 were excluded for a variety of reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy</title>
          <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
        </group>
        <group group_id="P2">
          <title>Drug Therapy Alone</title>
          <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline to 10 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Baseline to 8 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy</title>
          <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
        </group>
        <group group_id="B2">
          <title>Drug Therapy Alone</title>
          <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="307"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="14.2"/>
                    <measurement group_id="B2" value="58.0" spread="13.5"/>
                    <measurement group_id="B3" value="56.9" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Women Who Meet Definition of Success</title>
        <description>Proportion of women who meet definition of success: not taking drug or receiving other urge UI therapy (i.e., neuromodulation, botox injections, myomectomy, electrical stimulation, or any intravesical therapy) and not taking a tricyclic antidepressant or duloxetine at 8 months; and a &gt;70% reduction in number of incontinence episodes as compared to baseline.</description>
        <time_frame>8 months</time_frame>
        <population>All women who completed the 8 months assessment or were known to return to drug use prior to that time.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy Alone</title>
            <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Women Who Meet Definition of Success</title>
          <description>Proportion of women who meet definition of success: not taking drug or receiving other urge UI therapy (i.e., neuromodulation, botox injections, myomectomy, electrical stimulation, or any intravesical therapy) and not taking a tricyclic antidepressant or duloxetine at 8 months; and a &gt;70% reduction in number of incontinence episodes as compared to baseline.</description>
          <population>All women who completed the 8 months assessment or were known to return to drug use prior to that time.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan Meier Lifetable analysis was used to compute the 8 month cumulative success rates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Log Rank</method>
            <param_type>Difference in cumulative success rates</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incontinence Episodes</title>
        <description>Change from baseline to 10 weeks in number of incontinence episodes per week as reported on bladder diary.</description>
        <time_frame>Baseline and 10 weeks</time_frame>
        <population>All women with valid bladder diary at baseline and 10 weeks in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy Alone</title>
            <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incontinence Episodes</title>
          <description>Change from baseline to 10 weeks in number of incontinence episodes per week as reported on bladder diary.</description>
          <population>All women with valid bladder diary at baseline and 10 weeks in each treatment group.</population>
          <units>incontinence episodes per week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="1.4"/>
                    <measurement group_id="O2" value="-18.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of hypothesis of no difference in change in episodes between the two groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>Mixed effect repeated measures analysis of variance controlling for study site.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Voids Per Day</title>
        <description>Change from baseline to 10 weeks in frequency of voids per day as reported on bladder diary</description>
        <time_frame>baseline and 10 weeks</time_frame>
        <population>All women with valid bladder diary at baseline and 10 weeks in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy Alone</title>
            <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Voids Per Day</title>
          <description>Change from baseline to 10 weeks in frequency of voids per day as reported on bladder diary</description>
          <population>All women with valid bladder diary at baseline and 10 weeks in each treatment group.</population>
          <units>voids per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.4"/>
                    <measurement group_id="O2" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between arms in change in number of voids per day from baseline to 10 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>Repeated measures ANOVA controlling for clinical site.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Difference (group 1 - group 2) in change from baseline to follow-up in voids per day.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Distress</title>
        <description>Urogenital distress inventory (UDI). Higher score indicates greater distress. Possible range 0 to 300.</description>
        <time_frame>baseline, 10 weeks and 8 months</time_frame>
        <population>All women who completed UDI at each time in each treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Combination at Baseline</title>
            <description>Baseline value for women in combination therapy</description>
          </group>
          <group group_id="O2">
            <title>Combination at 10 Weeks</title>
            <description>10 week value for women in combination arm</description>
          </group>
          <group group_id="O3">
            <title>Combiniation at 8 Months</title>
            <description>8 months value from women in combination arm</description>
          </group>
          <group group_id="O4">
            <title>Drug Only at Baseline</title>
            <description>Baseline value for women randomized to drug only</description>
          </group>
          <group group_id="O5">
            <title>Drug Only at 10 Weeks</title>
            <description>10 week value for women randomized to drug only</description>
          </group>
          <group group_id="O6">
            <title>Drug Only at 8 Months</title>
            <description>8 month value for women randomized to drug only</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Distress</title>
          <description>Urogenital distress inventory (UDI). Higher score indicates greater distress. Possible range 0 to 300.</description>
          <population>All women who completed UDI at each time in each treatment group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="153"/>
                <count group_id="O5" value="136"/>
                <count group_id="O6" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.4" spread="3.8"/>
                    <measurement group_id="O2" value="47.3" spread="4.1"/>
                    <measurement group_id="O3" value="61.9" spread="4.3"/>
                    <measurement group_id="O4" value="118.2" spread="3.9"/>
                    <measurement group_id="O5" value="58.1" spread="4.0"/>
                    <measurement group_id="O6" value="83.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that there is no difference between treatment groups in improvement in UDI over time</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Repeated measures ANOVA</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Main hypothesis tested by F-test for treatment by time interaction (2 and 509 degrees of freedom). No parameters estimated.</method_desc>
            <param_type>Other</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Bother</title>
        <description>Disease specific overactive bladder scale (OAB-q). HIgher score indicates greater bother. Possible range 0 to 100.</description>
        <time_frame>baseline, 10 weeks and 8 months</time_frame>
        <population>Participants who completed OAB-q assessment at each time in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination at Baseline</title>
            <description>Baseline value for women in combination therapy</description>
          </group>
          <group group_id="O2">
            <title>Combination at 10 Weeks</title>
            <description>10 week value for women in combination arm</description>
          </group>
          <group group_id="O3">
            <title>Combiniation at 8 Months</title>
            <description>8 months value from women in combination arm</description>
          </group>
          <group group_id="O4">
            <title>Drug Only at Baseline</title>
            <description>Baseline value for women randomized to drug only</description>
          </group>
          <group group_id="O5">
            <title>Drug Only at 10 Weeks</title>
            <description>10 week value for women randomized to drug only</description>
          </group>
          <group group_id="O6">
            <title>Drug Only at 8 Months</title>
            <description>8 month value for women randomized to drug only</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Bother</title>
          <description>Disease specific overactive bladder scale (OAB-q). HIgher score indicates greater bother. Possible range 0 to 100.</description>
          <population>Participants who completed OAB-q assessment at each time in each treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="153"/>
                <count group_id="O5" value="136"/>
                <count group_id="O6" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" spread="1.7"/>
                    <measurement group_id="O2" value="23.1" spread="1.8"/>
                    <measurement group_id="O3" value="29.0" spread="1.9"/>
                    <measurement group_id="O4" value="60.0" spread="1.7"/>
                    <measurement group_id="O5" value="29.6" spread="1.7"/>
                    <measurement group_id="O6" value="39.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Repeated measures analysis of difference in symptom bother over time by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-value for test of time by treatment group interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for study site</method_desc>
            <param_type>Other</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>Number of women who responded &quot;completely satisfied&quot; to question, &quot;How satisfied are you with your progress?&quot;</description>
        <time_frame>10 weeks</time_frame>
        <population>Number of women who completed satisfaction question at 10 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination at 10 Weeks</title>
            <description>10 week value for women in combination arm</description>
          </group>
          <group group_id="O2">
            <title>Drug Only at 10 Weeks</title>
            <description>10 week value for women randomized to drug only</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction</title>
          <description>Number of women who responded &quot;completely satisfied&quot; to question, &quot;How satisfied are you with your progress?&quot;</description>
          <population>Number of women who completed satisfaction question at 10 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference in satisfaction at 10 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Controlling for clinical site and randomization stratum</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
            <estimate_desc>Ratio of odds of complete satisfaction in Combination therapy arm to Drug only arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>Number of women who responded &quot;completely satisfied&quot; to question &quot;How satisfied are you with your progress?&quot;</description>
        <time_frame>8 months</time_frame>
        <population>Number of participants who completed the 8 months satisfaction questions</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy Alone</title>
            <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction</title>
          <description>Number of women who responded &quot;completely satisfied&quot; to question &quot;How satisfied are you with your progress?&quot;</description>
          <population>Number of participants who completed the 8 months satisfaction questions</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in satisfaction at 8 months post intervention</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Controlling for clinical site and randomization stratum</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.70</ci_upper_limit>
            <estimate_desc>Ratio of odds of complete satisfaction in combination therapy group compared to drug only group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Improvement</title>
        <description>Number of women who responded &quot;much better&quot; or &quot;better&quot; to question: &quot;Overall, do you feel that you are much better, better, about the same, worse or much worse?&quot;</description>
        <time_frame>10 weeks</time_frame>
        <population>Participants who completed the satisfaction item at 10 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy Alone</title>
            <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Improvement</title>
          <description>Number of women who responded &quot;much better&quot; or &quot;better&quot; to question: &quot;Overall, do you feel that you are much better, better, about the same, worse or much worse?&quot;</description>
          <population>Participants who completed the satisfaction item at 10 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in perceived improvement between women in combination therapy group compared to those in drug only group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value from logistic regression analysis</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Controlling for clinical site and randomization stratum</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Improvement</title>
        <description>Number of women who responded &quot;much better&quot; or &quot;better&quot; to question: &quot;Overall, do you feel that you are much better, better, about the same, worse or much worse?&quot;</description>
        <time_frame>8 months</time_frame>
        <population>Participants who completed the perceived improvement item at 8 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy Alone</title>
            <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Improvement</title>
          <description>Number of women who responded &quot;much better&quot; or &quot;better&quot; to question: &quot;Overall, do you feel that you are much better, better, about the same, worse or much worse?&quot;</description>
          <population>Participants who completed the perceived improvement item at 8 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in perceived improvement at 8 months between women in combination therapy group compared to those in drug only group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Controlling for clinical site and randomization stratum</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>5.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for adverse events throughout the study period (8 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combination Therapy</title>
          <description>Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication and behavioral training.</description>
        </group>
        <group group_id="E2">
          <title>Drug Therapy Alone</title>
          <description>Women assigned to this arm received 10 weeks of anti-cholinergic medication, only.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowl obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncopal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Ony 68% of participants completed assigned treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anne Stoddard, ScD</name_or_title>
      <organization>New England Research Institutes</organization>
      <phone>617-972-3331</phone>
      <email>astoddard@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

